Suscribirse

Adherence and healthcare utilization among older adults with COPD and depression - 26/07/17

Doi : 10.1016/j.rmed.2017.06.002 
Jennifer S. Albrecht, PhD a, Bilal Khokhar, MA, PhD b, Ting-Ying Huang, PhD b, Yu-Jung Wei, PhD c, Ilene Harris, Pharm D, PhD d, Patience Moyo, MS b, Peter Hur, Pharm D b, Susan W. Lehmann, MD e, Giora Netzer, MD, MSCE a, f, Linda Simoni-Wastila, PhD b,
a Department of Epidemiology and Public Health, University of Maryland School of Medicine, United States 
b Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, United States 
c Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, United States 
d IMPAQ International LLC, Columbia, MD, United States 
e Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, United States 
f Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, United States 

Corresponding author. Department of Pharmaceutical Health Services Research, University of Maryland Baltimore School of Pharmacy, Saratoga Building, 12th Floor, 220 Arch Street, Baltimore, MD 21201, United States.Department of Pharmaceutical Health Services ResearchUniversity of Maryland Baltimore School of PharmacySaratoga Building12th Floor220 Arch StreetBaltimoreMD21201United States

Abstract

Background and objective

Adherence to chronic obstructive pulmonary disease (COPD) maintenance medications and antidepressants may reduce healthcare utilization among multimorbid individuals with COPD and depression. We quantified the independent effects of adherence to antidepressants and COPD maintenance medications on healthcare utilization among individuals co-diagnosed with COPD and depression.

Procedures

We conducted a retrospective cohort study using a 2006–2012 5% random sample of Medicare beneficiaries co-diagnosed with COPD and depression who had two or more prescription fills of both COPD maintenance medications and antidepressants. We measured adherence to medications using the proportion of days covered per 30-day period. The primary outcomes were all-cause emergency department (ED) visits and hospitalizations. Beneficiaries were followed over a minimum 12-month follow-up period.

Results

Of the 16,075 beneficiaries meeting inclusion criteria, 21% achieved adherence ≥80% to COPD maintenance medications and 55% achieved adherence ≥80% to antidepressants. Compared to no use and controlling for antidepressant adherence and potential confounders, higher (≥80%) levels of adherence to COPD maintenance medications were associated with decreased risk of ED visits (hazard ratio (HR) 0.79; 95% CI 0.74, 0.83) and hospitalizations (HR 0.82; 95% CI 0.78, 0.87). Similarly, higher levels (≥80%) of adherence to antidepressants resulted in decreased risk of ED visits (HR 0.74; 95% CI 0.70, 0.78) and hospitalizations (HR 0.77; 95% CI 0.73, 0.81) compared to no use.

Conclusions

Clinicians can assist in the improved management of their multimorbid patients' health by treating depression among patients with COPD and monitoring and encouraging adherence to the regimens they prescribe.

El texto completo de este artículo está disponible en PDF.

Highlights

1 in 5 older adults with COPD and depression achieve adherence of 80% or greater to COPD maintenance medications.
Antidepressant adherence was greater, with 1 in 2 older adults achieving adherence levels of 80% or better.
Higher adherence with both medications was associated with lower risk of emergency department visits and hospitalizations.
Understanding COPD and depression regimens may prevent unavoidable adverse events among depressed older adults with COPD.

El texto completo de este artículo está disponible en PDF.

Keywords : Chronic obstructive pulmonary disease, Medication adherence, Depression, Healthcare utilization


Esquema


© 2017  Elsevier Ltd. Reservados todos los derechos.
Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 129

P. 53-58 - août 2017 Regresar al número
Artículo precedente Artículo precedente
  • Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency
  • Sebastian Fähndrich, Nikolas Bernhard, Philipp M. Lepper, Claus Vogelmeier, Martina Seibert, Stefan Wagenpfeil, Robert Bals
| Artículo siguiente Artículo siguiente
  • Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: A review and recommendations for the conduct of future research
  • James Mahon, Anita Fitzgerald, Julie Glanville, Richard Dekhuijzen, Josefine Glatte, Sascha Glanemann, Saku Torvinen

¿Ya suscrito a @@106933@@ revista ?